Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘This Company Has Never Lost Its Ability To Develop New Medicines’
We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where ...
Regeneron Pharmaceuticals, Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / January 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc.(REGN) Shareholders
NEW YORK CITY, NY / ACCESS Newswire / January 21, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment ...
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Stock That Seems To Have Disappointed People. Bizarre’
We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are ...
Aaron Wealth Advisors LLC Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Aaron Wealth Advisors LLC cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 22.4% in the 4th quarter, according to its most recent disclosure with the Securities and ...
REGENERON EXPANDS PRESENCE IN CANADA BY OPENING ITS FIRST HEADQUARTERS TO BETTER SERVE NEEDS OF CANADIANS WITH SERIOUS DISEASES
NDAQ:REGN) REGENERON EXPANDS PRESENCE IN CANADA BY OPENING ITS FIRST HEADQUARTERS TO BETTER SERVE NEEDS OF CANADIANS WITH SERIOUS DISEASES ...
UBS cuts rating on Regeneron stock amid Eylea uncertainty
UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 from $1130.
Nasdaq8d
Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?
To counter the decline in Eylea sales, Regeneron developed a higher dose of the drug. While the initial uptake of Eylea HD was encouraging as Eylea patients transitioned to the higher dose ...
Regeneron Pharmaceuticals, Inc. Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the REGN Class Action
SAN DIEGO, CA / ACCESSWIRE / January 15, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all ...
Business Insider7d
Investors Who Hold Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Should Contact the Shareholders Foundation in Connection With Lawsuit
A lawsuit was filed for certain investors in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares. Investors in NASDAQ: REGN shares should contact the Shareholders Foundation at ...
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
Dupixent® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in ...
Regeneron Pharmaceuticals, Inc. (REGN) Securities Fraud: Contact Berger Montague To Discuss Your Rights
On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...